常見問題 Q&A

  1. 療效能維持多久? How long does BOTOX® effect last?

    BOTOX®保妥適®的去皺療程能持效達6個月18，你可按照自己的需要而重覆接受療程。當藥物療效漸漸消失後，皺紋會慢慢回復到尚未療程前的狀況，而不會變差。 BOTOX® treatment on wrinkles can last for up to 6 months18. You can repeat the treatment to achieve your desired results. After the BOTOX® effect wears off, your wrinkles will only gradually come back and will not get worse.

  2. 我想接受BOTOX®保妥適®療程，但我聽說它是由毒素製成的，它是否安全? I would like to receive BOTOX® treatment, but I heard that it was produced from a toxin. Is it safe?

    BOTOX®保妥適®是一種在嚴格監控下製造而成的高度純化蛋白質#，其全球臨床經驗長達30年，並獲美國FDA認證^，安全性在國際受到充分評估。 BOTOX® is a highly purified protein complex produced under strict laboratory rules and conditions#. With 30 years of clinical and experiences in the world, and being approved by the Food and Drug Administration (FDA) in the U.S.^, the safety of BOTOX® has been well-assessed.

  3. 若長期使用BOTOX®保妥適®，劑量會否一次比一次提高? Does BOTOX® dosing increase every treatment?

    不會，專業醫生每次會就療程的部位與肌肉收縮強度而決定所需劑量，臨床研究顥示，BOTOX®保妥適®會隨著療程次數的增加而延長效果的持續期，所以持續使用可逐漸減少療程的次數17。 No. The doctor tailors the dosage in accordance to the extent of muscle contraction for the required areas. Clinical studies show that the results of BOTOX® treatments last longer as the number of treatment increases, which can reduce the number of treatments gradually in the long run17.

  4. 會否造成面部肌肉僵硬? 面部肌肉會否受損? Does BOTOX® make your face stiff and damage your facial muscle?

    BOTOX®保妥適®只在療程部位產生作用, 針對性放鬆過於活躍的面部肌肉以達至去皺效果#, 正確使用下並不會引起面部僵硬及構成傷害。 BOTOX® only affects the treated areas. It does not make your face stiff under correct use. BOTOX® would just temporarily relax the overactive muscles on face in order to smooth away dynamic wrinkles#, therefore will not cause damage to facial muscles under correct use.

  5. BOTOX®保妥適®可與Juvéderm®透明質酸一起使用嗎？ Can BOTOX® botulinum toxin be used in conjunction with Juvéderm® hyaluronic acid?

    可以。同時使用2種療程可以達致更理想的效果。舉例來說，若眉心紋形成已久並出現靜態紋，建議先接受BOTOX®保妥適®療程使肌肉放鬆#，再接受Juvéderm®透明質酸療程來修飾靜態紋19-20，恢復平滑肌膚。 Yes. Treatment of BOTOX® and Juvéderm® at the sametime can enhance the treatment effect. For example, it is recommended to undergo the BOTOX® treatment to relax the muscle# which causes static frown lines, followed by treatment of Juvéderm® hyaluronic acid to fill up and smooth the static wrinkles away19-20.


使用條款 網站私隱聲明


‡: Medical Insight, Inc 2022. Cosmetic Neurotoxin Market Study. January 2022. Based on worldwide neurotoxins 2021 (in sales value). #: BOTOX® Prescribing Information. HK-41906. May 2013. Ɨ: Allergan Aesthetics. Data on File. REF-119535. Total number of BOTOX vials shipped as of 5 December 2022.
^: U.S. Food and Drug Administration, Department of Health & Human Services. Botox approval letter SUPPL-5303, October 2, 2017.
References: 1. Trindade de Almeida A et al. Dermatol Surg 2015; 41: S19-S28. 2. Yu W et al. J Cosmet Laser Ther. 2018Oct;20(5):278-286. 3. U.S. Food and Drug Administration, Department of Health & Human Services. Botox approval letter 85-0226 & 85-0227, December 29, 1989. 4. Allergan. Unpublished Data. INT-BCT-2050129 – Worldwide BOTOX® marketing authorization status. October 2020. 5. Allergan. Unpublished Data. REF-100250. BOTOX® number of peer-reviewed articles vs competitors. August 2022. 6. Michaud T, et al. J Cosmet Dermatol. 2015;14(1):9–21. 7. DasGupta BR. Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Decker, Inc; 1994: 15-39. 8. Coffield JA, Considine RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:3-13. 9. Schantz EJ, Johnson EA. Preparation and characterization of botulinum toxin type A for human treatment. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:41-49. 10. Simpson LL. The actions of clostridial toxins on storage and release of neurotransmitters. In: Harvey AL, ed. Natural and Synthetic Neurotoxins (Neuroscience Perspectives). San Diego, CA: Academic Press; 1993:278-317. 11. Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol. 1986;103(2):535-544. 12. Lebeda FJ, Hack DC, Bentry MK. Theoretical analyses of the functional regions of the heavy chain of botulinum neurotoxin. In: Jankovic J, Hallet M, ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:51-61. 13. Harvey AL. Presynaptic toxins. In: Smythies JR, Bradley RJ, ed. International Review of. 14. Neurobiology. San Diego, CA: Academic Press; 1990:201-239. 15. Tremaine AM, McCullough JL. Clin Cosmet Investig Dermatol. 2010;3:15–23. 16. Stotland MA et al. Plast Reconstr Surg 2007; 120(5):1386-9. 17. Beer KR et al. J Drugs Dermatol 2011;10:39-41. 18. De Boulle K et al. Dermatol Surg. 2018;44[11]:1437-1448. 19. De Maio M, et al. Plast Reconstr Surg. 2017 Aug;140(2):265e-276e. 20. Juvéderm® (Hyaluronic Acid Gel with Lidocaine) product series includes VOLUX™ (HKMD-190341), VOLUMA® (HKMD-100411), VOLIFT® (HKMD-130324), VOLBELLA® (HKMD-210451) and VOLITE™ (HKMD-180040).



BOTOX®保妥適®(Botulinum Toxin Type A)藥品註冊編號: HK-41906. BOTOX®為醫生處方藥物，請向醫生或醫學美容中心
諮詢切合您獨特需要的專屬療程方案。療程效果因人而異。療程後如有任何不良反應，請即向醫生查詢
© 2024 Allergan Aesthetics. All rights reserved. All adverse events should be reported to drugsafety.pv@abbvie.com.


HK-BCT-240047 | 30/SEP/24
香港北角電氣道 183 號友邦廣場 24 樓 2404-08 室        電話: (852)26102525



使用條款 網站私隱聲明

原廠供應的醫療中心